KIA
SRPT icon

Knollwood Investment Advisory’s Sarepta Therapeutics SRPT Stock Holding History

Knollwood Investment Advisory’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,400
Closed -$221K – 362
2024
Q2 		$221K Buy
+1,400
New +$180K 0.02% 339

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Knollwood Investment Advisory's SRPT Position: Q3 2024 in Review

Knollwood Investment Advisory sold out of Sarepta Therapeutics (SRPT) in Q3 2024, closing a stake of 1,400 shares — an estimated $221K sold.

Knollwood Investment Advisory first reported a position in SRPT in Q2 2024 and held it in 1 quarter. The position peaked at $221K in Q2 2024. 458 funds tracked by Wall St. Rank hold SRPT as of Q3 2024.

  • Knollwood Investment Advisory reported no remaining Sarepta Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Knollwood Investment Advisory sold 1,400 Sarepta Therapeutics shares in Q3 2024, an estimated $221K.
  • Knollwood Investment Advisory first reported a position in Sarepta Therapeutics in Q2 2024 and held it in 1 quarter.
  • Knollwood Investment Advisory's Sarepta Therapeutics position peaked at $221K in Q2 2024.
  • 458 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2024.

Based on Knollwood Investment Advisory's 13F filing for Q3 2024, filed 14 Nov 2024.